Literature DB >> 24885857

Which combination of MR imaging modalities is best for predicting recurrent glioblastoma? Study of diagnostic accuracy and reproducibility.

Ho Sung Kim1, Myeong Ju Goh, Namkug Kim, Choong Gon Choi, Sang Joon Kim, Jeong Hoon Kim.   

Abstract

PURPOSE: To compare the added value of dynamic contrast material-enhanced ( CE contrast enhanced ) ( DCE dynamic CE ) magnetic resonance (MR) imaging with that of dynamic susceptibility CE contrast enhanced ( DSC dynamic susceptibility CE ) MR imaging with the combination of CE contrast enhanced T1-weighted imaging and diffusion-weighted ( DW diffusion weighted ) imaging for predicting recurrent glioblastoma.
MATERIALS AND METHODS: This retrospective study was approved by the institutional review board, with the requirement for informed patient consent waived. CE contrast enhanced T1-weighted images, DW diffusion weighted images, DSC dynamic susceptibility CE MR images, and DCE dynamic CE MR images in 169 patients with pathologically or clinicoradiologically diagnosed recurrent glioblastoma (n = 87) or radiation necrosis (n = 82) were retrospectively reviewed. Histogram cutoffs of quantitative parametric values were calculated from DW diffusion weighted images, DSC dynamic susceptibility CE MR images, and DCE dynamic CE MR images. Area under the receiver operating characteristic curve ( Az area under the ROC curve ) and interreader agreement were assessed.
RESULTS: For predicting recurrent glioblastoma, adding DCE dynamic CE MR imaging to the combination of CE contrast enhanced T1-weighted imaging and DW diffusion weighted imaging significantly improved Az area under the ROC curve from 0.84 to 0.96 for reader 1 and from 0.81 to 0.97 for reader 2, respectively. Adding DSC dynamic susceptibility CE MR imaging also significantly improved Az area under the ROC curve (0.95 for reader 1 and 0.93 for reader 2). However, there was no significant difference in Az between the combination of CE contrast enhanced T1-weighted imaging, DW diffusion weighted imaging, and DSC dynamic susceptibility CE MR imaging and the combination of CE contrast enhanced T1-weighted imaging, DW diffusion weighted imaging, and DCE dynamic CE MR imaging for both readers. The interreader agreement was highest for the combination of CE contrast enhanced T1-weighted imaging, DW diffusion weighted imaging, and DCE dynamic CE MR imaging (κ = 0.78) and lowest for CE contrast enhanced T1-weighted imaging and DW diffusion weighted imaging (κ = 0.65).
CONCLUSION: Adding perfusion MR imaging to the combination of CE contrast enhanced T1-weighted imaging and DW diffusion weighted imaging significantly improves the prediction of recurrent glioblastoma; however, selection of perfusion MR method does not affect the diagnostic performance. © RSNA, 2014.

Entities:  

Mesh:

Year:  2014        PMID: 24885857     DOI: 10.1148/radiol.14132868

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  41 in total

1.  Loss of Pericytes in Radiation Necrosis after Glioblastoma Treatments.

Authors:  Soon-Tae Lee; Youngbeom Seo; Ji-Yeon Bae; Kon Chu; Jin Wook Kim; Seung Hong Choi; Tae Min Kim; Il Han Kim; Sung-Hye Park; Chul-Kee Park
Journal:  Mol Neurobiol       Date:  2017-08-02       Impact factor: 5.590

Review 2.  Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.

Authors:  Mark S Shiroishi; Jerrold L Boxerman; Whitney B Pope
Journal:  Neuro Oncol       Date:  2015-09-12       Impact factor: 12.300

3.  Comparison of Diffusion Tensor Imaging and Magnetic Resonance Perfusion Imaging in Differentiating Recurrent Brain Neoplasm From Radiation Necrosis.

Authors:  William R Masch; Page I Wang; Thomas L Chenevert; Larry Junck; Christina Tsien; Jason A Heth; Pia C Sundgren
Journal:  Acad Radiol       Date:  2016-02-23       Impact factor: 3.173

4.  Which is the best advanced MR imaging protocol for predicting recurrent metastatic brain tumor following gamma-knife radiosurgery: focused on perfusion method.

Authors:  Myeong Ju Koh; Ho Sung Kim; Choong Gon Choi; Sang Joon Kim
Journal:  Neuroradiology       Date:  2015-01-16       Impact factor: 2.804

Review 5.  MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis.

Authors:  Praneil Patel; Hediyeh Baradaran; Diana Delgado; Gulce Askin; Paul Christos; Apostolos John Tsiouris; Ajay Gupta
Journal:  Neuro Oncol       Date:  2016-08-08       Impact factor: 12.300

6.  Differentiation of residual/recurrent gliomas from postradiation necrosis with arterial spin labeling and diffusion tensor magnetic resonance imaging-derived metrics.

Authors:  Ahmed Abdel Khalek Abdel Razek; Lamiaa El-Serougy; Mohamed Abdelsalam; Gada Gaballa; Mona Talaat
Journal:  Neuroradiology       Date:  2017-12-07       Impact factor: 2.804

Review 7.  An Update on the Approach to the Imaging of Brain Tumors.

Authors:  Katherine M Mullen; Raymond Y Huang
Journal:  Curr Neurol Neurosci Rep       Date:  2017-07       Impact factor: 5.081

8.  Vascular Reactivity Maps in Patients with Gliomas Using Breath-Holding BOLD fMRI.

Authors:  Amir Iranmahboob; Kyung K Peck; Nicole P Brennan; Sasan Karimi; Ryan Fisicaro; Bob Hou; Andrei I Holodny
Journal:  J Neuroimaging       Date:  2016 Mar-Apr       Impact factor: 2.486

9.  Differentiation of recurrent diffuse glioma from treatment-induced change using amide proton transfer imaging: incremental value to diffusion and perfusion parameters.

Authors:  Yae Won Park; Sung Soo Ahn; Eui Hyun Kim; Seok-Gu Kang; Jong Hee Chang; Se Hoon Kim; Jinyuan Zhou; Seung-Koo Lee
Journal:  Neuroradiology       Date:  2020-09-02       Impact factor: 2.804

Review 10.  Diagnostic Performance of PET and Perfusion-Weighted Imaging in Differentiating Tumor Recurrence or Progression from Radiation Necrosis in Posttreatment Gliomas: A Review of Literature.

Authors:  N Soni; M Ora; N Mohindra; Y Menda; G Bathla
Journal:  AJNR Am J Neuroradiol       Date:  2020-08-27       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.